cp-778875
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00326326)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
PPARA agonist
Status last updated May 2009, discontinued?
Chemistry & pharmacology
Loading structure…
SMILES
CCc1ccc(CSc2ccc(NS(=O)(=O)c3ccc(C)c(C(=O)O)c3)cc2)cc1- Mol. weight
- 441.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314385 ↗
- ChEMBLCHEMBL3545276 ↗
Also known as
- 5-(n-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid
- cp-778875
- cp-778875
- cp-778,875
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00326326 | Phase 2 | Jul 1, 2006 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1